Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its partner Everest Medicines (HKEX: 1952.HK) ("Everest") announced that China's National Medical Products Administration (NMPA) has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.China has the highest prevalence of primary glomerular diseases in the world with an estimated five million IgAN patients. There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian